GlassScriptPhysician profile
Sadhis Rivas
NPI 1659445427
$4,489.22
in general payments reported to CMS, 2019-2025
40 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $461 · 2021: $548 · 2022: $1,024 · 2023: $434 · 2024: $357 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $651.91 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $435.74 | 2019-2023 | Fasenra |
| Lilly USA, LLC | $356.06 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Mannkind Corporation | $351.83 | 2019-2020 | |
| Abbvie INC. | $304.00 | 2019-2024 | Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.88 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $227.05 | 2021-2025 | |
| Novo Nordisk INC | $193.17 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Insulet Corporation | $190.61 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $142.96 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Sanofi-Aventis U.S. LLC | $136.84 | 2022-2023 | |
| Grifols USA, LLC | $124.83 | 2019 | |
| Medtronic, INC. | $110.30 | 2022-2025 | Minimed 780g |
| Glaxosmithkline, LLC. | $98.60 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Recordati_rare_diseases_inc. | $94.96 | 2021-2024 | Signifor Lar, Isturisa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadhis Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.